Hormone replacement therapy and haemostatic function

Thrombosis and Haemostasis

Volumn 78, Issue 1, 1997, Pages 765-769

  Meade, T W ^a,b  

^a ST BARTHOLOMEW S HOSPITAL   (United Kingdom)

^b MEDICAL RESEARCH COUNCIL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTITHROMBIN III; BLOOD CLOTTING FACTOR 7; ESTROGEN; FIBRINOGEN; GESTAGEN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; MEDROXYPROGESTERONE ACETATE; NORGESTREL; PROGESTERONE;

CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONFERENCE PAPER; DEEP VEIN THROMBOSIS; DRUG FORMULATION; ESTROGEN THERAPY; FEMALE; HEART PROTECTION; HEMOSTASIS; HORMONE DEFICIENCY; HORMONE SUBSTITUTION; HUMAN; INTRAVAGINAL DRUG ADMINISTRATION; LUNG EMBOLISM; ORAL DRUG ADMINISTRATION; POSTMENOPAUSE; PRIORITY JOURNAL; SYSTOLIC BLOOD PRESSURE; TRANSDERMAL DRUG ADMINISTRATION;

EID: 0030841131     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0038-1657626     Document Type: Conference Paper

References (19)

1. Falkeborn M, Persson I, Adami HO et al. The risk of acute myocardial infarction after oestrogen and oestrogen-progestogen replacement. Br J Obstet & Gynaecol, 1992; 99:821-828.
2. Grodstein F, Stampfer MJ, Manson JE, Colditz GA, Willett WC, Rosner B, Speizer FE, Hennekens CH. Postmenopausal estrogen and progestin use and the risk of cardiovascular disease. N Engl J Med, 1996;335:453-461.
3. Falkeborn M, Persson I, Terent A et al. Hormone replacement therapy and the risk of stroke. Arch Intern Med, 1993; 153: 1201-1209.
4. Daly E, Vessey MP, Hawkins MM, Carson JL, Gough P, Marsh S. Risk of venous thromboembolism in users of hormone replacement therapy. Lancet, 1996;348: 977-980.
5. Jick H, Derby LE, Myers MW, Vasilakis C, Newton KM. Risk of hospital admission for idiopathic venous thromboembolism among users of postmenopausal oestrogens. Lancet, 1996;348:981-983.
6. Daly E, Vessey MP, Painter R, Hawkins MM. Case-control study of venous thromboembolism risk in users of hormone replacement therapy. Lancet, 1996;348: 1027.
7. Pérez Gutthann S, Garcia Rodriguez LA, Castellsague J, Oliart AD. Hormone replacement therapy and risk of venous thromboembolism: population based case-control study. Br Med J, 1997; 314:796-800
8. Grodstein F, Stampfer MJ, Goldhaber SZ, Manson JE, Colditz GA, Speizer FE, Willett WC, Hennekens CH. Prospective study of exogenous hormones and risk of pulmonary embolism in women. Lancet, 1996;348:983-987.
9. Spitzer WO, Lewis MA, Heinemann LAJ, Thorogood M, MacRae KD, Third generation oral contraceptives and risk of venous thromboembolic disorders: an international case-control study. Br Med J, 11996;312:83-88.
10. Lewis MA, Spitzer WO, Heinemann LAJ, MacRae KD, Bruppacher R, Thorogood M. Third generation oral contraceptives and risk of myocardial infarction: an international case-control study. Br Med J, 1996;312:88-90.
11. Medical Research Vouncil's General Practice Research Framework. Randomised comparison of oestrogen versus oestrogen plus progestogen hormone replacement therapy in hysterectomised women. Report from MRC's General Practice Research Framework. Br Med J, 1996:312:473-478.
12. The Writing Group for the PEPI Trial. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. JAMA, 1995; 273:199-208.
13. Munk-Jensen N, Ulrich LG, Obel EB, Neilsen SP, Edwards D, Meinertz H. Continuous combined and sequential estradiol and norethindrone acetate treatment of postmenopausal women: effect on plasma lipoprotein in a two-year placebo-controlled trial. Am J Obstet Gynecol, 1994;171: 132-138.
14. Caine YG, Bauer KA, Barzegar S, et al. Coagulation activation following estrogen administration of postmenopausal women. Thromb & Haemostas, 1992;68:392-395.
15. Kroon U-B, Silfverstolpe G, Tengborn L. The effects of transdermal estradiol and oral conjugated estrogens on haemostasis variables. Thromb & Haemostas, 1994,71: 420-423.
16. The Writing Group for the Estradiol Clotting Factors Study. Effects on haemostasis of hormone replacement therapy with transdermal estradiol and oral sequential medroxyprogesterone acetate: a 1-year, double-blind, placebo-controlled study. Thromb Haemostas, 1996;75:476-480.
17. Scarabin PY, Alhenc-Gelas M, Plu-Burean G, Taisne P, Agher R, Aiach M. Activation of blood coagulation and increased fibrinolytic potential induced by oral but not percutaneous estrogen/progesterone replacement therapy in postmenopausal women: a randomised controled trial. Haemostasis, 1996; 26:466.
18. Koh KK, Mincemoyer R, Bull MN, Csako G, Pucino F, Guetta V, Waclawiw M, Cannon RO. Effects of hormone-replacement therapy on fibrinolysis in postmenopausal women. N Engl J Med, 1997; 336:683-690.
19. Nabulsi AA, Folsom AR, White A, Patsch W, Heiss G, Wu KK, Szklo M. Association of hormone-replacement therapy with various cardiovascular risk factors in postmenopausal women. N Engl J Med, 1993; 328:1069-1075.